QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
NASDAQ:IMGN

ImmunoGen (IMGN) Stock Price, News & Analysis

$31.23
0.00 (0.00%)
(As of 02/12/2024)
Today's Range
$31.22
$31.25
50-Day Range
$29.26
$31.23
52-Week Range
$3.61
$31.25
Volume
48.61 million shs
Average Volume
8.78 million shs
Market Capitalization
$8.32 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.77

ImmunoGen MarketRank™ Stock Analysis

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
17.5% Downside
$25.77 Price Target
Short Interest
Bearish
7.74% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.86
Upright™ Environmental Score
News Sentiment
0.81mentions of ImmunoGen in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$9.90 M Sold Last Quarter
Proj. Earnings Growth
362.50%
From $0.08 to $0.37 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.03 out of 5 stars

Medical Sector

188th out of 934 stocks

Biotechnology Industry

5th out of 24 stocks


IMGN stock logo

About ImmunoGen Stock (NASDAQ:IMGN)

ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.

IMGN Stock Price History

IMGN Stock News Headlines

The Gold Story No One's Telling
Gold research firm says we could see much higher gold in 2024. "We'll show you the best possible way to play the current surge in gold for just $5." 
CERE Aug 2024 30.000 call
ImmunoGen (NASDAQ:IMGN) Research Coverage Started at StockNews.com
Barclays Keeps Their Hold Rating on ImmunoGen (IMGN)
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE!
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets…FOR FREE!
IMGN Quantitative Stock Analysis
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EAR, IMGN, CVLY
Immunogen Inc IMGN
AbbVie acquiring Cerevel Therapeutics in $8.7B deal
ImmunoGen downgraded to Neutral from Overweight at Piper Sandler
See More Headlines
Receive IMGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmunoGen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
7/31/2023
Today
2/22/2024
Next Earnings (Estimated)
3/06/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:IMGN
CUSIP
45253H10
Employees
277
Year Founded
1981

Price Target and Rating

Average Stock Price Target
$25.77
High Stock Price Target
$31.26
Low Stock Price Target
$16.00
Potential Upside/Downside
-17.5%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
12 Analysts

Profitability

Net Income
$-222,930,000.00
Pretax Margin
-25.24%

Debt

Sales & Book Value

Annual Sales
$108.78 million
Book Value
$0.71 per share

Miscellaneous

Free Float
252,764,000
Market Cap
$8.32 billion
Optionable
Optionable
Beta
1.18

Social Links

7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives















IMGN Stock Analysis - Frequently Asked Questions

Should I buy or sell ImmunoGen stock right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ImmunoGen in the last twelve months. There are currently 9 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" IMGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IMGN, but not buy additional shares or sell existing shares.
View IMGN analyst ratings
or view top-rated stocks.

What is ImmunoGen's stock price target for 2024?

12 brokerages have issued 1-year price objectives for ImmunoGen's stock. Their IMGN share price targets range from $16.00 to $31.26. On average, they predict the company's share price to reach $25.77 in the next year. This suggests that the stock has a possible downside of 17.5%.
View analysts price targets for IMGN
or view top-rated stocks among Wall Street analysts.

How have IMGN shares performed in 2024?

ImmunoGen's stock was trading at $29.65 on January 1st, 2024. Since then, IMGN stock has increased by 5.3% and is now trading at $31.23.
View the best growth stocks for 2024 here
.

Are investors shorting ImmunoGen?

ImmunoGen saw a increase in short interest during the month of January. As of January 31st, there was short interest totaling 20,610,000 shares, an increase of 9.3% from the January 15th total of 18,860,000 shares. Based on an average daily trading volume, of 8,180,000 shares, the days-to-cover ratio is currently 2.5 days.
View ImmunoGen's Short Interest
.

When is ImmunoGen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 6th 2024.
View our IMGN earnings forecast
.

How were ImmunoGen's earnings last quarter?

ImmunoGen, Inc. (NASDAQ:IMGN) issued its quarterly earnings data on Monday, July, 31st. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.14. The biotechnology company earned $83.20 million during the quarter, compared to analyst estimates of $49.15 million. ImmunoGen had a negative trailing twelve-month return on equity of 22.11% and a negative net margin of 25.56%. The company's revenue for the quarter was up 485.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.24) EPS.

What is Mark J. Enyedy's approval rating as ImmunoGen's CEO?

16 employees have rated ImmunoGen Chief Executive Officer Mark J. Enyedy on Glassdoor.com. Mark J. Enyedy has an approval rating of 64% among the company's employees.

What other stocks do shareholders of ImmunoGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ImmunoGen investors own include Pfizer (PFE), NVIDIA (NVDA), Micron Technology (MU), Immunomedics (IMMU), Advanced Micro Devices (AMD), AbbVie (ABBV), Gilead Sciences (GILD), OPKO Health (OPK), AT&T (T) and Dynavax Technologies (DVAX).

Who are ImmunoGen's major shareholders?

ImmunoGen's stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (9.56%), Norges Bank (2.08%), FIL Ltd (2.01%), Voloridge Investment Management LLC (1.21%), Northern Trust Corp (0.87%) and TIG Advisors LLC (0.87%). Insiders that own company stock include Kristine Peterson, Mark J Enyedy, Renee Lentini, Stacy Ann Coen and Theresa Wingrove.
View institutional ownership trends
.

How do I buy shares of ImmunoGen?

Shares of IMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does ImmunoGen have any subsidiaries?
The following companies are subsidiares of ImmunoGen: Hurricane LLC, ImmunoGen BioPharma (Ireland) Limited, ImmunoGen Europe Limited, and ImmunoGen Securities Corp..
Read More
This page (NASDAQ:IMGN) was last updated on 2/22/2024 by MarketBeat.com Staff